<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190811044513N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-09-11</date_registration>
      <primary_sponsor>Hamedan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of zinc supplements on the oxidative stress and reduction of withdrawal symptoms in opioid addicts in the withdrawal syndrome</public_title>
      <acronym></acronym>
      <scientific_title>The effect of zinc supplements on the oxidative stress and reduction of withdrawal symptoms in opioid addicts in the withdrawal syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-08-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/41513</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: For this purpose we will use quadratic random blocks method. For this purpose, we provide four sheets of paper for each drug and placebo group separately. We write on two sheets of letter A (intervention group) and on the other two sheets of letter C (comparison group). Mix the sheets together and place in a drawer. By referring to each eligible patient, one sheet was randomly drawn and the A or C sheet was drawn according to one of the two groups (zinc recipient) and control group Will be allocated. It should be noted that the drawn sheets will not be returned to the drawer until all four sheets have been drawn. Once the four sheets have been randomly pulled out, all the sheets are returned to the drawer and the procedure will be repeated for the next four patients until the desired sample size is reached, Blinding description: Patients in the intervention group received 30 mg zinc pills without awareness. The other group uses medication that is a form and color with zinc tablets. Also, the treating physician who will examine patients will not be aware of the type of medication used for patients. In addition, the statistical analyst will not be aware of the drug code used. Therefore, this study will be a triple blind.</study_design>
      <phase>3</phase>
      <hc_freetext>People with Opioid Addiction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Opioid addicts who use 30 mg zinc tablets from the US company Naturemade. The pill is given to each patient during one month and one pill for each day. It is recommended to take the pill at night and after dinner to better absorb and reduce the gastrointestinal side effects. Blood sampling was performed once before the intervention and once after the intervention. Intervention 2: Control group: The control group is opioid addicts who use a placebo that completely similar to zinc tablets during one month and one pill for each day. This placebo was made at the Faculty of Pharmacy, Hamadan University of Medical Sciences. It is recommended to be taken at night and after dinner in order to better absorb and reduce the gastrointestinal side effects. Blood sampling was performed once before the intervention and once after the intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is I haven't decided yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Hasanalizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Fahmide Ave, Hamadan University of Medical Sciences, Faculty of Pharmacy</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517838678</zip>
        <telephone>+98 81 3838 1591</telephone>
        <email>alizadeh01996@gmail.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sara Ataei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Fahmide Ave, Hamadan University of Medical Sciences, Faculty of Pharmacy</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517838678</zip>
        <telephone>+98 81 3838 1591</telephone>
        <email>s.ataei@umsha.ac.ir</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Opioid use for two years and more
Admission within a maximum of one week from the time of withdrawal
Not taking medications away from the specialist opinion
Absence of acute and chronic inflammatory diseases and any other acute or chronic infections
Lack of AIDS, hepatitis and diabetes</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Re-consuming by people before sampling
Use of drugs that have an effect on inflammation and oxidative stress
Getting any disease during research
Attempted suicide or a history of it during the past year</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z.81-4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Family history of other substance abuse</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Opioid addicts who use 30 mg zinc tablets from the US company Naturemade. The pill is given to each patient during one month and one pill for each day. It is recommended to take the pill at night and after dinner to better absorb and reduce the gastrointestinal side effects. Blood sampling was performed once before the intervention and once after the intervention.</i_keyword>
      <i_keyword>Control group: The control group is opioid addicts who use a placebo that completely similar to zinc tablets during one month and one pill for each day. This placebo was made at the Faculty of Pharmacy, Hamadan University of Medical Sciences. It is recommended to be taken at night and after dinner in order to better absorb and reduce the gastrointestinal side effects. Blood sampling was performed once before the intervention and once after the intervention.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Oxidative stress factors, reduction of withdrawal symptoms. Timepoint: At the beginning and end of the study. Method of measurement: Serum level measurement  by using kits.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Antioxidant capacity of serum. Timepoint: At the beginning and end of the study. Method of measurement: Colorimetric method.</sec_outcome>
      <sec_outcome>Lipid Peroxidation Index. Timepoint: At the beginning and end of the study. Method of measurement: Colorimetric method.</sec_outcome>
      <sec_outcome>Thiol groups index. Timepoint: At the beginning and end of the study. Method of measurement: Colorimetric method.</sec_outcome>
      <sec_outcome>Enzymatic activity of glutathione peroxidase. Timepoint: At the beginning and end of the study. Method of measurement: Colorimetric method.</sec_outcome>
      <sec_outcome>Enzymatic activity of superoxide dismutase. Timepoint: At the beginning and end of the study. Method of measurement: Colorimetric method.</sec_outcome>
      <sec_outcome>Evaluation of withdrawal symptoms. Timepoint: At the beginning and end of the study. Method of measurement: COWS questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Hamedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-07-05</approval_date>
        <contact_name>Ethics committee of HamadanUniversity of Medical Sciences</contact_name>
        <contact_address>Shahid Fahmide Ave, Hamadan University of Medical Sciences, Faculty of Pharmacy Hamadan Hamadan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
